Bioserenity

Bioserenity

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Bioserenity is a private, commercial-stage company offering a vertically integrated platform for neurology and sleep diagnostics, combining FDA/CE-certified hardware, AI software, and telemedicine services. Founded in 2014, it has established a network of 200+ hospital partners and a community of 9,000 physicians, processing 60,000 remote interpretations in 2023. The company is leveraging its large real-world electrophysiology database to develop AI foundation models, positioning itself at the intersection of medical devices, diagnostics, and digital health.

NeurologySleep DisordersCardiology

Technology Platform

Integrated platform combining connected medical devices (EEG caps, portable Neuronaute+ system), a cloud-based AI software suite for data analysis, and a telemedicine network for remote specialist interpretation.

Opportunities

The global shift towards decentralized, home-based care and remote patient monitoring creates a massive tailwind for Bioserenity's platform.
Its large, real-world electrophysiology dataset provides a unique competitive moat for developing superior AI diagnostic tools, potentially opening new revenue streams from data insights and algorithm licensing.

Risk Factors

The company faces significant regulatory complexity in certifying both its hardware and AI software across different markets.
Slower-than-expected adoption and reimbursement for remote diagnostic protocols by healthcare payers could hinder growth, and the space is becoming increasingly competitive.

Competitive Landscape

Bioserenity competes with traditional medical device companies selling EEG systems, other digital health startups offering remote monitoring solutions, and tech companies developing AI for healthcare. Its integrated hardware-software-telemedicine model and focus on neurology/sleep provide differentiation, but it must continuously innovate to stay ahead.